PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma

Table 1 Univariate and Multivariate analysis in the training cohort (n = 358)

Variables	Univariate analysis	Multivariate analysis
	Univariate analysis	A		B		C
	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
Liver cirrhosis (no vs. yes)	0.030	0.816 (0.418–1.591)	0.550	0.816 (0.418–1.591)	0.550	0.871 (0.449–1.688)	0.682
Serum ALT, U/L (≤ 40 vs. > 40)	0.001	0.534 (0.335–0.848)	0.008	0.534 (0.335–0.848)	0.008	0.552 (0.346–0.879)	0.012
γ-GT, U/L (> 75 vs. ≤ 75)	0.023	1.295 (0.883–1.898)	0.185	1.295 (0.883–1.898)	0.185	1.257 (0.856–1.846)	0.243
Tumor size (cm) (> 5 vs. ≤ 5)	< 0.0001	1.984 (1.461–2.696)	< 0.0001	1.984 (1.461–2.696)	< 0.0001	2.006 (1.474–2.729)	< 0.0001
Tumor number (multiple vs. single)	0.001	1.451 (1.006–2.092)	0.046	1.451 (1.006–2.092)	0.046	1.432 (0.993–2.064)	0.054
Vascular invasion (yes vs. no)	< 0.0001	1.701 (1.254–2.307)	0.001	1.701 (1.254–2.307)	0.001	1.695 (1.250–2.300)	0.001
TNM stage (I vs. II-III)	< 0.0001	0.799 (0.388–1.647)	0.543	0.799 (0.388–1.647)	0.543	0.831 (0.404–1.710)	0.615
CD8⁺PD1^Int/ CD8⁺PD1⁺ (high vs. low)	0.005	0.686 (0.497–0.947)	0.022
CD8⁺PD1^Hi/ CD8⁺PD1⁺ (high vs. low)	0.005			1.458 (1.056–2.013)	0.022
CD8⁺TIM3⁺ PD1^Hi/ CD8⁺PD1⁺ (high vs. low)	0.002					1.476 (1.085–2.008)	0.013

Abbreviations: ALT Alanine transaminase, γ-GT Gamma-Glutamyl-transpeptidase, TNM Tumor-nodes-metastases, HR Hazard ratio, CI Confidential interval. A:CD8⁺PD1^Int/ CD8⁺PD1⁺; B:CD8⁺PD1^Hi/ CD8⁺PD1⁺; C:CD8⁺TIM3⁺PD1^Hi/ CD8⁺PD1⁺. Multivariate analysis was performed by the Cox multivariate proportional hazard regression model with stepwise manner